Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

Yueyao Jiang; Chengran Wang; Chuancheng Zu; Xin'ao Rong; Qian Yu; Jinlan Jiang

doi:10.2147/ijn.s466396

journal article Open Access Oct 01, 2024

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

Yueyao Jiang Chengran Wang Chuancheng Zu Xin'ao Rong Qian Yu

Jinlan Jiang

International Journal of Nanomedicine Vol. Volume 19 pp. 9459-9486 · Informa UK Limited

View at Publisher Save 10.2147/ijn.s466396

Topics

No keywords indexed for this article. Browse by subject →

References

211

[1]

Cancer statistics, 2023

Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al.

CA: A Cancer Journal for Clinicians 2023 10.3322/caac.21763

[2]

Chowdhury Targ Oncol (2020) 10.1007/s11523-020-00720-2

[3]

Gillessen Europ urol (2020) 10.1016/j.eururo.2020.01.012

[4]

Nuhn Europ urol (2019) 10.1016/j.eururo.2018.03.028

[5]

Cancer Immunotherapy.

[6]

Zhang Cell Mol Immunol (2020) 10.1038/s41423-020-0488-6

[7]

Saxena Nat Rev Cancer (2021) 10.1038/s41568-021-00346-0

[8]

Mitsogiannis Expert opin biol ther (2022) 10.1080/14712598.2022.2027904

[9]

Irvine Nat Rev Immunol (2020) 10.1038/s41577-019-0269-6

[10]

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow, Robert Sidlow, Matthew D. Hellmann

New England Journal of Medicine 2018 10.1056/nejmra1703481

[11]

Pfirschke Immunity (2016) 10.1016/j.immuni.2015.11.024

[12]

Thakor CA a Cancer J Clinicians (2013) 10.3322/caac.21199

[13]

Dai j biomed nanotechnol (2020) 10.1166/jbn.2020.2965

[14]

Parvani Cancer Res (2015) 10.1158/0008-5472.can-14-3485

[15]

Meng Nanoscale (2023) 10.1039/d2nr07071e

[16]

Buschmann Vaccines (2021) 10.3390/vaccines9010065

[17]

Wang Adv Mater (2023) 10.1002/adma.202210948

[18]

Adekiya Front Bioeng Biotechnol (2020) 10.3389/fbioe.2020.00032

[19]

Xie ACS Nano (2019) 10.1021/acsnano.8b03788

[20]

Shi Acc Chem Res (2019) 10.1021/acs.accounts.9b00148

[21]

Wong Asian J. Pharm Sci (2022) 10.1016/j.ajps.2022.04.005

[22]

Ni Nat Biomed Eng (2022) 10.1038/s41551-022-00846-w

[23]

Boyd Nat Rev Urol (2012) 10.1038/nrurol.2012.185

[24]

Cai Drug Resist Updates (2023) 10.1016/j.drup.2023.100962

[25]

Marín-Aguilera Mol Cancer Ther (2014) 10.1158/1535-7163.mct-13-0775

[26]

Ayoubi‐Joshaghani Adv Funct Mater (2020) 10.1002/adfm.202004098

[27]

Bailey Adv Healthcare Materials (2017) 10.1002/adhm.201601418

[28]

Abramson Nat Rev Immunol (2024) 10.1038/s41577-023-00906-5

[29]

Rosalia Cancer Immunol Immunother (2013) 10.1007/s00262-013-1411-0

[30]

Blank Intl Journal of Cancer (2006) 10.1002/ijc.21775

[31]

Kroon Cancer Treat Rev (2014) 10.1016/j.ctrv.2013.10.005

[32]

Saneja Mater Sci Eng C (2019) 10.1016/j.msec.2019.01.026

[33]

Jiang Expert Opin Drug Delivery (2016) 10.1517/17425247.2016.1134486

[34]

Yao Front Mol Biosci (2020) 10.3389/fmolb.2020.00193

[35]

Mohamed Isa Pharmaceutics (2021) 10.3390/pharmaceutics13020152

[36]

Pilch ACS Appl Mater Interfaces (2020) 10.1021/acsami.0c02621

[37]

Murugesan CDD (2022) 10.2174/1567201818666210224101456

[38]

Fang Adv Drug Delivery Rev (2011) 10.1016/j.addr.2010.04.009

[39]

Maeda Adv Drug Delivery Rev (2015) 10.1016/j.addr.2015.01.002

[40]

Clemons Langmuir (2018) 10.1021/acs.langmuir.8b02946

[41]

Ni Nat Commun (2018) 10.1038/s41467-018-04703-w

[42]

Kroon Prostate (2015) 10.1002/pros.22963

[43]

In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery

Akhlesh K. Jain, Suresh Thareja

Artificial Cells, Nanomedicine, and Biotechnology 2019 10.1080/21691401.2018.1561457

[44]

Yoo ACS Biomater Sci Eng (2020) 10.1021/acsbiomaterials.0c01228

[45]

Yan Small (2015) 10.1002/smll.201501412

[46]

Nassir Saudi Pharm J (2018) 10.1016/j.jsps.2018.03.009

[47]

Abbasi Nanoscale Res Lett (2014) 10.1186/1556-276x-9-247

[48]

Shalmani Drug Deliv Transl Res 10.1007/s13346-023-01465-x

[49]

Thambiraj Sci Rep (2021) 10.1038/s41598-020-80529-1

[50]

Thipe IJN (2019) 10.2147/ijn.s204443

Showing 50 of 211 references

Cited By

28

Next-generation nanocarriers for colorectal cancer: passive, active, and stimuli-responsive strategies for precision therapy

Rehab Galal Abbas Mohamed, Salma Mohamed Ali · 2025

Biomaterials Science

Metrics

28

Citations

211

References

Details

Published: Oct 01, 2024
Vol/Issue: Volume 19
Pages: 9459-9486
License: View

Authors

Beijing Institute of Technology

J

Jinlan Jiang

Cite This Article

Yueyao Jiang, Chengran Wang, Chuancheng Zu, et al. (2024). Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects. International Journal of Nanomedicine, Volume 19, 9459-9486. https://doi.org/10.2147/ijn.s466396

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

You May Also Like